Press "Enter" to skip to content

Glenmark gets USFDA nod for generic skin inflammation treatment foam

Citing IQVIA sales data, Glenmark said, Olux foam 0.05 per cent achieved annual sales of approximately USD 50.9 million in the 12-month period ended December 2018.

Original source: https://health.economictimes.indiatimes.com/news/pharma/glenmark-gets-usfda-nod-for-generic-skin-inflammation-treatment-foam/68050311?utm_source=RSS&utm_medium=ETRSS

Also Read:   Jan Aushadhi scheme may disrupt 20% of Indian pharma market sales: Report